TY - JOUR
T1 - Treatment of Diabetes in Older Adults
T2 - An Endocrine Society
AU - Leroith, Derek
AU - Biessels, Geert Jan
AU - Braithwaite, Susan S.
AU - Casanueva, Felipe F.
AU - Draznin, Boris
AU - Halter, Jeffrey B.
AU - Hirsch, Irl B.
AU - Mcdonnell, Marie E.
AU - Molitch, Mark E.
AU - Murad, M. Hassan
AU - Sinclair, Alan J.
N1 - Funding Information:
The guideline writing committee thanks the participating organizations and individuals with diabetes for their invaluable contribution to the patient voice in this guideline. We particularly thank the Reverend Albert Whitaker from the ADA’s Senior Signature program, Ronald H. Lammy from the Total Wellness for Elders Program at the Elder HealthCare Disparities Coalition (Roxbury, MA), and Sarah Mart from Diabetes Sisters. The writing committee thanks the cosponsors of this guideline for their contribution to the development effort. The Endocrine Society acknowledges that the American Geriatrics Society (AGS) affirms the value of this document. (Affirmation of value means that AGS supports the general principles in this document and believes it is of general benefit to its membership.) Financial Support: This guideline was supported by the Endocrine Society. No other entity provided financial support.
Publisher Copyright:
© 2019 Endocrine Society.
PY - 2019
Y1 - 2019
N2 - Objective: The objective is to formulate clinical practice guidelines for the treatment of diabetes in older adults. Conclusions: Diabetes, particularly type 2, is becoming more prevalent in the general population, especially in individuals over the age of 65 years. The underlying pathophysiology of the disease in these patients is exacerbated by the direct effects of aging on metabolic regulation. Similarly, aging effects interact with diabetes to accelerate the progression of many common diabetes complications. Each section in this guideline covers all aspects of the etiology and available evidence, primarily from controlled trials, on therapeutic options and outcomes in this population. The goal is to give guidance to practicing health care providers that will benefit patients with diabetes (both type 1 and type 2), paying particular attention to avoiding unnecessary and/or harmful adverse effects.
AB - Objective: The objective is to formulate clinical practice guidelines for the treatment of diabetes in older adults. Conclusions: Diabetes, particularly type 2, is becoming more prevalent in the general population, especially in individuals over the age of 65 years. The underlying pathophysiology of the disease in these patients is exacerbated by the direct effects of aging on metabolic regulation. Similarly, aging effects interact with diabetes to accelerate the progression of many common diabetes complications. Each section in this guideline covers all aspects of the etiology and available evidence, primarily from controlled trials, on therapeutic options and outcomes in this population. The goal is to give guidance to practicing health care providers that will benefit patients with diabetes (both type 1 and type 2), paying particular attention to avoiding unnecessary and/or harmful adverse effects.
UR - http://www.scopus.com/inward/record.url?scp=85063923523&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063923523&partnerID=8YFLogxK
U2 - 10.1210/jc.2019-00198
DO - 10.1210/jc.2019-00198
M3 - Article
C2 - 30903688
AN - SCOPUS:85063923523
SN - 0021-972X
VL - 104
SP - 1520
EP - 1574
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 5
ER -
